Non-Hodgkin's Lymphoma among Patients Infected with Human Immunodeficiency Virus: The Experience of a Single Center in Brazil

Paula Yurie Tanaka, Luis Fernando Pracchia, Edenilson Eduardo Calore

Int J Hematol. 2006;84(4):337-342.

“With the EPOCH regimen, Little et al described the best response rate (87%) and OS rate (87% at 56 months) to date for patients with CD4 cell counts $>100/\mu\text{L}$; however, the outcomes were worse for patients with CD4 cell counts $<100/\mu\text{L}$ (OS rate of 16% at 56 months) [13-15].”

The authors wish to correct the information in their manuscript to:

“With the EPOCH regimen, Little et al described the best response rate (87%) and OS rate (87% at 53 months) to date for patients with CD4 cell counts $>100/\mu\text{L}$; however, the outcomes were worse for patients with CD4 cell counts $<100/\mu\text{L}$ (OS rate of 16% at 53 months) [13-15].”